Compare Amazon.com Inc (AMZN) vs Sanofi SA (SNY) Price & Performance

Amazon (AMZN) trades at $244.19, down 0.47% on the day but maintains strong bullish technical momentum with support at $241. The company demonstrates robust fundamentals with 2025 revenue of $716.92B and net income of $77.67B, representing 10.83% profit margin. Recent Q1 2026 earnings beat expectations with EPS of $2.78 versus $1.63 expected, while analyst consensus remains overwhelmingly positive with 88.3% buy ratings.

Amazon's outlook remains favorable with continued revenue growth and expanding profitability, though significant capital expenditures for AI infrastructure and competitive pressures in e-commerce present risks. The stock trades at a P/E of 29.35, offering growth potential relative to the consensus price target of $320.75, representing 31% upside from current levels.

SNY trades at $43.50, down 0.91% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.10 vs. $1.06 expected, and maintains robust profitability with 71.92% gross margin and 15.95% net margin. Recent FDA approval for Sarclisa's subcutaneous formulation provides growth catalyst.

SNY presents a compelling investment case with solid earnings performance and pipeline advancements, though regulatory scrutiny in Europe and patent expiration risks for key drug Dupixent in 2031 warrant monitoring. Analyst consensus leans positive with 44% buy ratings, supporting a constructive outlook for long-term investors.